Anti-drug antibodies

Biological pharmaceuticals are increasingly used in modern medicine and give remarkable improvements for many different patient groups. Unfortunately, for several of these compounds, undesirable immune reactions are induced against the drug. The resulting anti-drug antibodies modify the pharmacokinetic and pharmacodynamic properties of the drug and, by blocking the drug-target interaction, reduce the effects of the treatment. Anti-drug antibodies may also increase the risk of hypersensitivity reactions by the formation of immune complexes. Furthermore, by cross-reacting with the endogenous homolog of the drug, the anti-drug antibodies might impair important physiological functions even after treatment cessation. As a consequence, anti-drug antibodies need to be taken in account when estimating the benefit-burden ratio of a treatment for an individual patient, but also when calculating the value of therapeutics on a socio-economic level. In this review we give an overview over the current understanding of the immunogenicity against drugs, exemplified for patients with hemophilia A, multiple sclerosis, rheumatoid arthritis and Crohn’s disease. We discuss known and potential risk factors for anti-drug antibody formation and finally outline suggested strategies for prediction and prevention.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-09-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.4081/DTS.2012.E11
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients

  2013cited by this paper
• Anti‐TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics‐Based Dosing Paradigms

  2012cited by this paper
• Immunogenicity of biological therapeutics: from assay to patient

  2012cited by this paper
• Requirements for immune recognition and processing of factor VIII by antigen-presenting cells.

  2012cited by this paper
• Immunogenicity of Therapeutic Proteins: The Use of Animal Models

  2011cited by this paper
• Quantitative analysis of the CD4 T‐cell repertoire specific to therapeutic antibodies in healthy donors

  2011cited by this paper
• Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.

  2011cited by this paper
• Dendritic Cells and Damage-Associated Molecular Patterns: Endogenous Danger Signals Linking Innate and Adaptive Immunity

  2011cited by this paper
• Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab

  2011cited by this paper
• Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion.

  2011cited by this paper
• Immune tolerance in multiple sclerosis

  2011cited by this paper
• Assessing Response and Loss of Response to Biological Therapies in IBD

  2011cited by this paper
• Differential effect of drug interference in immunogenicity assays.

  2011cited by this paper
• Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis.

  2011cited by this paper
• Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

  2011cited by this paper
• Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.

  2011cited by this paper
• The ever-expanding list of HLA alleles: changing HLA nomenclature and its relevance to clinical transplantation.

  2011cited by this paper
• Determinants of interferon β efficacy in patients with multiple sclerosis

  2011cited by this paper
• Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists.

  2011cited by this paper
• Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients

  2011cited by this paper
• Factor VIII inhibitors: a 50‐year perspective

  2011cited by this paper
• Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo.

  2010cited by this paper
• Critical review: assessment of interferon-β immunogenicity in multiple sclerosis.

  2010cited by this paper
• Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.

  2010cited by this paper
• Immunological mechanism underlying the immune response to recombinant human protein therapeutics.

  2010cited by this paper
• Th17 immune responses contribute to the pathophysiology of aplastic anemia.

  2010cited by this paper
• Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII.

  2010cited by this paper
• Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.

  2010cited by this paper
• Unwanted immunogenicity: lessons learned and future challenges.

  2010cited by this paper
• Control systems and decision making for antibody production

  2010cited by this paper
• On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis

  2010cited by this paper
• Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.

  2010cited by this paper
• The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful

  2010cited by this paper
• Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

  2010cited by this paper
• Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study

  2009cited by this paper
• Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.

  2009cited by this paper
• Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice.

  2009cited by this paper
• Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review

  2009cited by this paper
• Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia A

  2009cited by this paper
• Inhibitor development: patient‐determined risk factors

  2009cited by this paper
• Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

  2009cited by this paper
• A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis

  2009cited by this paper
• Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β

  2009cited by this paper
• High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study

  2009cited by this paper
• Dealing with immunogenicity of biologicals: assessment and clinical relevance

  2009cited by this paper
• Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells

  2009cited by this paper
• Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

  2008cited by this paper
• Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells.

  2008cited by this paper
• Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies?

  2008cited by this paper
• Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease

  2008cited by this paper
• Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

  2008cited by this paper
• HLA-DRB1∗0401 and HLA-DRB1∗0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis

  2008cited by this paper
• International workshop on immune tolerance induction: consensus recommendations 1

  2007cited by this paper
• In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

  2007cited by this paper
• EDITOR’S QUIZ: GI SNAPSHOT

  2007cited by this paper
• Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.

  2007cited by this paper
• Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

  2007cited by this paper
• The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.

  2007cited by this paper
• Epoetin-induced pure red cell aplasia: diagnosis and treatment

  2007cited by this paper
• A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes

  2007cited by this paper
• Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.

  2007cited by this paper
• Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.

  2007cited by this paper
• The incidence and significance of anti-natalizumab antibodies

  2007cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

  2006cited by this paper
• Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.

  2006cited by this paper
• Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia

  2006cited by this paper
• Immunogenicity, efficacy and adverse events of adalimumab in RA patients

  2006cited by this paper
• Natalizumab induction and maintenance therapy for Crohn's disease.

  2005cited by this paper
• Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.

  2005cited by this paper
• Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus.

  2005cited by this paper
• Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders.

  2004cited by this paper
• Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

  2004cited by this paper
• A mouse model of human adaptive immune functions: HLA‐A2.1‐/HLA‐DR1‐transgenic H‐2 class I‐/class II‐knockout mice

  2004cited by this paper
• In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody.

  2004cited by this paper
• Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

  2004cited by this paper
• Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

  2004cited by this paper
• Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.

  2004cited by this paper
• Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis

  2004cited by this paper
• Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-β Does Not Result in an In Vivo Response Directed at the Subdominant Epitope

  2004cited by this paper
• Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS

  2004cited by this paper
• Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

  2003cited by this paper
• Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

  2003cited by this paper
• Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

  2003cited by this paper
• The epidemiology of inhibitors in haemophilia A: a systematic review

  2003cited by this paper
• Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

  2002cited by this paper
• Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis

  2002cited by this paper
• Enbrel (etanercept).

  2002cited by this paper
• Bioequivalence and the immunogenicity of biopharmaceuticals

  2002cited by this paper
• Thrombocytopenia caused by the development of antibodies to thrombopoietin.

  2001cited by this paper
• Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

  2001cited by this paper
• Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group.

  2000cited by this paper
• Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration

  2000cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation

  1995cited by this paper

• Sequential redox strategies for enhanced defluorination and degradation of a Trifluoromethylated Pharmaceutical using a single bimetallic catalyst.

  2025cites this paper
• Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology

  2022cites this paper
• Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics.

  2019cites this paper
• Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - A tutorial.

  2019cites this paper
• Application of Liquid Chromatography-High Resolution Mass Spectrometry in the Quantification of Intact Proteins in Biological Fluids

  2017cites this paper
• Impact économique des biosimilaires d'anti-TNFalpha à l'échelle des établissements adhérents du groupement de commandes PharmAlp'Ain

  2016cites this paper
• Individualized antimetastatic therapy [1–2]

  2015cites this paper
• 6 – Drug combinations

  2015cites this paper
• Anticancer drug combinations : The next medical challenge

  2015cites this paper
• Individualized cancer chemotherapy via cancer biomarkers or bioinformatics detection

  2015cites this paper
• Recent advances in absolute quantification of peptides and proteins using LC-MS

  2014cites this paper
• Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer.

  2014cites this paper
• Personalized Cancer Therapy: A Perspective

  2014cites this paper
• Individualized cancer therapy

  2014cites this paper
• Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards

  2013cites this paper
• Accurate and rapid micro fl uidic ELISA to monitor In fl iximab titers in patients with in fl ammatory bowel diseases

  year unknowncites this paper